Navigation Links
Ovarian cancer stem cell study puts targeted therapies within reach
Date:1/6/2013

Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis. The study, which paves the way for developing novel targeted ovarian cancer therapies, is published online in the current issue of Cell Cycle.

Lead author Yingqun Huang, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences, and her colleagues have demonstrated a connection between two concepts that are revolutionizing the way cancer is treated.

First, the "cancer stem cell" idea suggests that at the heart of every tumor there is a small subset of difficult-to-identify tumor cells that fuel the growth of the bulk of the tumor. This concept predicts that ordinary therapies typically kill the bulk of tumor cells while leaving a rich environment for continued growth of the stem cell tumor population.

The second concept, dubbed "seed and soil," defines a critical role for the tumor cells' "microenvironment," which is the special environment required for cancer cell growth and spread.

"Both concepts have particular relevance for the treatment of adult solid tumors such as ovarian cancer, which has been notoriously difficult to diagnose and treat," said co-author Nita J. Maihle, M.D., professor in the Department of Obstetrics, Gynecology & Reproductive Sciences and a member of Yale Cancer Center. "Ovarian cancer patients are plagued by recurrences of tumor cells that are resistant to chemotherapy, ultimately leading to uncontrolled cancer growth and death."

In this study, Huang and her colleagues were able to define a molecular basis for the interplay between these two concepts in ovarian cancer. They did this by using sophisticated gene sequencing methods to demonstrate a regulatory link between the stem cell factor Lin28 and the signaling molecule bone morphogenic protein 4 (BMP4).

"These results are supported by the latest molecular ovarian cancer prognosis data, which also suggest an active role for the tumor microenvironment in ovarian carcinogenesis," said Huang and Maihle. "Together these studies reveal new targets for the development of cancer therapies."


'/>"/>

Contact: Karen N. Peart
karen.peart@hotmail.com
203-432-1326
Yale University
Source:Eurekalert

Related medicine news :

1. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
2. U.S. Panel Rejects Ovarian Cancer Screening
3. UC Irvine study finds racial, economic disparities in ovarian cancer care, survival
4. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
5. The prevention of hereditary breast and ovarian cancer by PGD is feasible
6. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
7. Ovarian Transplants May Preserve Fertility in Young Cancer Survivors
8. Benefit of PET and PET/CT in ovarian cancer is not proven
9. Mechanisms of acquired chemoresistance in ovarian cancer identified
10. U.S. Panel Rejects Ovarian Cancer Screens for Low-Risk Women
11. Simple ovarian cancer symptom survey that checks for 6 warning signs may improve early detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , ... May 03, 2016 , ... ... announced that it has been honored as one of the nation’s most accomplished ... InformationWeek Elite 100. Horizon received the recognition for technology achievements that have enabled ...
(Date:5/3/2016)... ... May 03, 2016 , ... BioPlus Specialty Pharmacy ... at the 2016 Asembia Specialty Pharmacy Summit held May 2-6, 2016 at the ... health care conference for the specialty pharmacy industry, with thousands of pharmacy providers, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Empyrean Benefit Solutions, Inc., the ... service center in La Vergne, Tennessee, near Nashville. The new center will complement ... Empyrean client services. , “Our Nashville-area center allows us to achieve several goals,” ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Park Cities ... live in or adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, ... Greenway Parks, Bluffview, Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... one of Canada’s top Information and Communication Technology (ICT) companies in the annual ... Multinational ICT companies operating in Canada, as ranked by revenue. , “We ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
(Date:4/29/2016)... , April 29, 2016 ... H1 2016" market research report that provides an ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology ... appointment of Dr. Alfredo Zurlo as Chief ... with many years clinical experience and a proven track ... role was at Mologen AG where he was Chief ... Dr. Zurlo held various positions at F Hoffmann La ...
Breaking Medicine Technology: